Vertex Pharmaceuticals (VRTX)
(Real Time Quote from BATS)
$449.65 USD
-7.30 (-1.60%)
Updated May 28, 2024 10:50 AM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Brokerage Reports
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 301 - 320 ( 326 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Initiating Coverage with a Buy Rating and Price Target of $45
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
2010 AASLD Abstract Titles Review - Second Wave Including Late-Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Boceprevir Topline May Be a Temporary Relief to Vertex
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals -2010 AASLD Abstract Titles Review - First Wave Without Late Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Lowering PT to $40 on Anticipated Stronger Competition
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Interim TMC435 Data Impressive; Remains a Strong Competitor to Telaprevir Although >2 Years Behind
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
ADVANCE Is As Good As It Can Get - Upgrade to Relative -NEUTRAL on Minimized Downside Risk.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Bulls and Bears Balancing Out at EASL - What to Expect Next?
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings Non-Event; Phase III Data Next
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
EASL 2010 Preview Part I.Summary of Oral Presentations.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K